Chapter 4 Financing Forum

  "Next, please welcome Mr. Deng Qun, Director and General Manager of Beigene Investment, to share with us the latest developments in the domestic biopharmaceutical investment and financing field, as well as how a renowned investment company in the biopharmaceutical field selects its investment targets."

  Deng Qun smiled and stood up, walking to the front of the stage. "In 2009, the biotechnology and biochemical manufacturing industry achieved a main business income of nearly 80 billion yuan, with profits exceeding 10 billion yuan. Despite the financial crisis, we still achieved growth rates of over 30% and 40%, respectively. This shows that in the field of biological medicine, as an emerging pharmaceutical market, our prospects are excellent. However, the development of China's biopharmaceutical industry is also facing bottlenecks, especially in terms of changing its development model.

  Currently, there are many domestic biopharmaceutical companies, but they are mostly concentrated on low-level repetitive construction, with a lack of modernization in production and scattered research and development capabilities. Until now, we have not escaped the circle of imitation drugs. In order for China's biopharmaceutical industry to continue its healthy and sustainable development, it must change the current situation where biopharmaceutical companies are too small and mixed.

  The high-end biopharmaceutical industry is capital-intensive, requiring large amounts of funding to support new drug screening, research and development, and production. Of course, this comes with high risks, but also faces high returns. Therefore, I think today's investment forum is very meaningful, allowing enterprises and industrial investors to have more opportunities for exchange."

  Applause...

  Deng Qun scanned the crowd with a smile, "Of course, as an investment company interested in the biopharmaceutical industry, we also have some suggestions for companies currently engaged in biopharmaceuticals or developing in this direction. Our investment company is not a government agency that distributes subsidies and industrial development funds. We will take every investment project seriously and screen them carefully. Our research team will also have genuine expert advisors. As an investment company, we must be responsible to our investors. So, I suggest that companies that are used to dealing with government agencies in a perfunctory manner should not use the same approach when dealing with us. The tactics of finding a molecular activity screening, using liquid chromatography-mass spectrometry to obtain a small amount of active substance, abusing a group of mice, setting up a compression workshop, and doing everything within 100 square meters will not work here. I sincerely hope that entrepreneurs can have a longer-term vision and do things in a down-to-earth manner. Although the total sales of domestic gene engineering drugs are not even close to the annual output value of a medium-sized company in the United States or Japan, I still hope that you can break free from short-term interests and have greater courage. We may not be able to become Pfizer, Merck, or Novartis for the time being, but CRO (contract research organization) is a direction, and infiltrating new drug development through the CRO industry is a shortcut. I can reveal a piece of news to everyone: American new drug research company CRLI will acquire Pharmacon for $1.6 billion, which is an exciting message. This makes us believe that whether it's developing and growing into a company like Pharmacon that sells for a good price or continuing to become China's Pfizer, Merck, it will bring rich returns to investors..."

  Deng Qun walked down from the applause and patted Wu Lun's shoulder, "You're really calm."

  Wu Lun still crossed his arms over his chest, "You've explained it very well, but there's one thing I don't understand."

  "What?"

  "What are your standards? When an American company acquires a domestic CRO company at a high price, you say that the direction of CRO is correct. But if the other party gives up on the acquisition, will you then turn around and say otherwise?"

  Deng Qun burst out laughing, "Do you think CRLI's acquisition of Yao Kang is a joke? If the other party wants to breach the contract, they will have to pay 30 million US dollars in compensation. This is no small sum."

  Wu Lun smiled and shook his head, saying no more. He looked up at the director of a research center on stage, who was using a projector to present his research data.

  Deng Qun's eyebrows slightly furrowed.

  The forum ended, and Deng Qun never thought that this young man could be more calm than him. This person can casually put people aside and ignore them, is it because he's inexperienced or naive? It doesn't seem like it, Deng Qun felt belittled, although he couldn't control the other person, but at least he was a senior in investment!

  Wu Lun made a phone call to the driver and went to the underground parking lot, Deng Qun was also on the way, but Wu Lun treated him as a stranger. Deng Qun smiled and said, "What's wrong? We were chatting just now, and now we have nothing to say."

  Wu Lun shrugged and smiled, "My words can't penetrate the shell of your stubbornness, saying more won't make a difference."

  Deng Qun was taken aback for a moment, then smiled and said, "I just so happen to have some business in Chongqing, you can ride with me, it's always more interesting to have someone to talk to on the road." Deng Qun raised his hand, and the Audi A6 not far away beeped.

  "No need, the company has a car." Wu Lun saw the driver coming over just in time.

  Deng Qun didn't say anything more, but turned to the driver and said with a smile, "Driver Wang, you go back first, I'll send Manager Wu back."

  The driver was taken aback, with a look of surprise, but quickly regained his composure, hastily piling on smiles and hurriedly agreeing. Wu Lun's words of refusal were stuck in his throat as he watched Wang, the driver, fawn over Deng Qun, knowing that he definitely wouldn't listen to himself, and if he insisted, it would only lead to embarrassment for himself.

  Cheng Lu sent the guest away, closed the door with a lazy stretch, revealing her curves and full elasticity, but no man had the chance to see Cheng Lu like this. She put down her hand, gently rubbed her eyebrows, and hung up the internal line, "Help me make a cup of coffee."

  A burst of laughter over the phone, "Drink some juice, didn't you buy a juicer? Let me remind you to use it."

  "Whatever, get something, make some orange juice, add a few ice cubes."

  "No problem." He chuckled over the phone, and soon Sun Jia came in with two cups of orange juice, handing one to Cheng Lü. Sun Jia sipped her orange juice, glancing around Cheng Lü's office as she usually did, "Your office isn't much bigger than that fake degree holder's, I just don't get it, why give him such a great office."

  "It was originally for Yue Zheng, but he insisted on sharing an office with Li Wen. Anyway, it's idle, and Wu Lun won't last long either. If you don't want to be my assistant in the future, you can move there."

  "Don't you call him a fake academic?"

  "Let me ask you this, is Beyo really not sold domestically?"

  Sun Jia looked wronged, "Really didn't, my brother in the US booked it several weeks in advance and bought it at Macy's, it was limited edition, now this thing is already sold out, can't be bought anymore, who knew that guy could sniff it out, really has a dog nose."

  Cheng Lu didn't want to get entangled in this matter, glanced at her watch and asked, "Has that person come back?"

  Sun Jia's eyes lit up, sparkling with some excitement, "Guess who he came back with?"

  Cheng Lu waved her hand, "Not interested." She handed the cup to Sun Jia, "You can leave now."

  Sun Jia pouted and walked to the door, dropping a sentence as she left, "He came back with Deng Qun."

  Cheng Lu was taken aback, and at the same time, the phone on the table rang.

  [Thanks to Mu Tian Shui for proofreading]